 Connection
Yuwen Zhu to Immunotherapy
This is a "connection" page, showing publications Yuwen Zhu has written about Immunotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.114 |
|
|
|
-
Torphy RJ, Schulick RD, Zhu Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int J Mol Sci. 2017 Dec 06; 18(12).
Score: 0.417
-
Dickinson K, Yee EJ, Vigil I, Schulick RD, Zhu Y. GPCRs: emerging targets for novel T cell immune checkpoint therapy. Cancer Immunol Immunother. 2024 Oct 03; 73(12):253.
Score: 0.167
-
Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Nat Commun. 2022 01 10; 13(1):97.
Score: 0.138
-
Fujiwara Y, Torphy RJ, Sun Y, Miller EN, Ho F, Borcherding N, Wu T, Torres RM, Zhang W, Schulick RD, Zhu Y. The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun. 2021 10 06; 12(1):5857.
Score: 0.136
-
Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, Lugano R, Miller EN, Fujiwara Y, Bian L, Zheng L, Anand S, Gao F, Zhang W, Ferrara SE, Goodspeed AE, Dimberg A, Wang XJ, Edil BH, Barnett CC, Schulick RD, Chen L, Zhu Y. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sci Transl Med. 2021 07 28; 13(604).
Score: 0.134
-
Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog. 2020 07; 59(7):775-782.
Score: 0.122
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|